Mert Aktar - May 29, 2025 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role
Director
Signature
By: /s/ Ryan Jones, as Attorney-in-Fact
Stock symbol
KYTX
Transactions as of
May 29, 2025
Transactions value $
$0
Form type
4
Date filed
6/2/2025, 06:32 PM
Previous filing
Oct 24, 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Aktar Mert Director C/O KYVERNA THERAPEUTICS, INC., 5980 HORTON ST., STE 550, EMERYVILLE By: /s/ Ryan Jones, as Attorney-in-Fact 2025-06-02 0002040256

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYTX Common Stock Award $0 +16.6K $0.00 16.6K May 29, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYTX Stock Option (right to buy) Award $0 +65.4K $0.00 65.4K May 29, 2025 Common Stock 65.4K $2.63 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
F2 All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.